- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jennifer Brown on the Role of Genomic Sequencing in CLL
Jennifer R. Brown, MD, PhD, director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, discusses how genomic sequencing plays a role in determining prognosis and treatment for patients with chronic lymphocytic leukemia (CLL).
Jennifer R. Brown, MD, PhD, director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, discusses how genomic sequencing plays a role in determining prognosis and treatment for patients with chronic lymphocytic leukemia (CLL).
TranscriptDoes genomic sequencing play a role in determining prognosis and treatment for patients with chronic lymphocytic leukemia?
Certainly, certain genomic prognostic markers are quite important in CLL [chronic lymphocytic leukemia]. Historically, we’ve used chromosome abnormalities as determined by FISH [Fluorescence In Situ Hybridization], with the highest risk abnormality being the deletion of 17p. Now, that’s often accompanied by mutation of the TP53 gene, which we now recognize being similarly adverse to 17p deletion. One thing that was remarkable about venetoclax and rituximab is that there was no difference in progression-free survival (PFS) at 2 or 3 years based on 17p deletion.
That’s actually even better than the BTK [Bruton's Tyrosine Kinase] inhibitors where we actually do see that PFS is a bit shorter in the patients with that very high-risk marker. There are other gene mutations in CLL, as well. NOTCH1 is one that we worry about associated with Richter’s transformation, SF3B1, and ATM. And then a long list of less frequent mutations. We don’t really know yet what the impact of those are in the context of novel agent therapy, and that’s something that we’re all very interested still in studying.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
